Should dupilumab treatment for atopic dermatitis patients
be suspended or modified during the COVID-19 pandemic?
The current EAACI statement on the usage of biologicals in the context
of COVID-19 advices no change of therapy in non-infected individuals and
to withhold/delay the application of biologicals for a minimum of two
weeks or the resolution of the disease in case of SARS-CoV-2
infection.44 This is based on expert opinion in the
light of missing data and may be adapted if more information becomes
available.